Continuous Functions
3.3 Min-max and intermediate value theorems Note: 1.5 lectures
67
CHAPTER SIX
CONCLUSION AND RECOMMENDATION
68
REFERENCES
1. El Nahas AM, Bello AK. Chronic Kidney disease: The global challenge.
Lancet 2005; 365:331-340.
2. Levey AS, Eckardt KU, Tsukamotto Y, Levin A, Coresh J, Rossert J et al Definition and Classification of Chronic Kidney Disease : A position statement from kidney disease improving global outcome (KDIGO) Kid.
Intern. 2005;67: 2089 – 2090
3. Coresh J, Byrd-Holt D, Astor BC , Briggs JP, Eggers PW, Lacher DA et al.
Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J. Am Soc Nephrol. 2005; 16: 180-188.
4. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med 2006;
354:2473-2483.
5. Akinsola A, Odesanmi WO, Ogunniyi JO, Ladipo GOA. Diseases causing renal failure in Nigeria. A prospective study of 100 consecutive cases.
African J. Med. Sci. 1989; 18:131-137.
6. Oyediran AB, Akinkugbe OO. Chronic renal failure in Nigeria. Trop. Geog.
Med. 1970; 22:41-44.
7. Alebiosu CO, Ayodele OO, Abbas A, Ina OA. Chronic Renal Failure at the Olabisi Onabanjo University Teaching Hospital. Afri Health Sci; 2006;
6:132-138.
8. Keith D, Nicholls G, Guillion C. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern med 2004; 164: 659-663.
9. Rohm DD. Is atherosclerosis accelerated in haemodialysis patients? Int. J.
Artg. Organs. 1992; 15:323-326.
69
10. Charnwy DI, Walton DF, Cheung AK. Atherosclerosis in chronic renal failure. Curr. Open. Nephrol. Hypertens. 1993; 2:876-882.
11. Vasilis T, Zoi M, Moses E. Dyslipidemia associated with Chronic Kidney Disease. The Open Cardiovascular Medicine Journal 2011; 5: 41-48.
12. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE.
Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996;49:1428 –34.
13. Nosratole DV, Mohamad N, Alan MF. HDL Metabolism and activity in Chronic Kidney Disease. Nat Rev Nephrol 2010; 6:287-296.
14. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005;16:529 –38.
15. Go AS., Chertow GM, Fan D, McCulloch CE, Hsu,C. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization.N Engl J Med 2004; 351:1296-1305
16. European Artherosclerosis Society. International Task Force for Prevention of coronary heart disease, scientific background and new clinical guidelines. Nutr Metab Cardiovascular Dis, 1992; 2:113-156.
17. Report of WHO Scientific Group; Cardiovascular disease risk factors; new areas for research. WHO Technical Report Series. No 841. WHO Geneva 1994.
18. Snively CS, Gutierrez C. CKD: Prevention and Treatment of Common Complications. Am Fam Physician 2004; 70 (10): 1921-s8.
70
19. Vasilis T, Evangelia D, Costas CS. Dyslipidemia in Chronic Kidney Disease: An approach to pathogenesis and Treatment. Am J Nephrol 2008; 28: 958-973.
20. Zolezzi M. Management of Dyslipidemia in Renal Disease and Transplantation. Saudi J Kidney Dis Transpl 2006;17:129-36.
21. Ugbodaga PF, Oviasu E, Ojogwu LI, serum lipoproteins pattern in nephrotic Nigerians. Journ Of Nephrology 1995: 8(6): 331-333 .
22. Dena R, Mark S. Should all patients with CKD take a statin? One minute Consult 2008; 75 (2): 118-20.
23. Shurraw S, Tonelli M. Statins for treatment of Dyslipidemia in CKD. Perit Dial Int 2006; 26 (5): 523-539.
24. Weiner DE, Sarnak MJ. Managing Dyslipidemia in CKD. J Gen Intern Med 2004; 19 (10): 1045-52.
25. Mannon R.B. Post-transplantation Monitoring and Outcomes. Primer on Kidney Disease, 5th Edition; 2009; 63:539.
27. Mshelia DS, Buratai LB, Mamza YP. Lipid profile in predialysis Chronic Kidney Disease patients attending University of Maiduguri Teaching Hospital Nigeria. Niger J Clin Pract. 2009; 12 (2) 173-8.
28. Kaba ML, Diakite M, Bah AO, Sylla IS. Dyslipidemia in Uremic patients at the National Hospital of Donka Conakry. Mali Med 2007; 22 (2): 6-9.
71
29. Pennel P, Leclercq B, Delahunty MI, Walter BAJ. The Utility of non-HDL in managing dyslipidemia of Stage 5 Chronic Kidney Disease. Clinical Nephrology 2006; 66: 336-347.
30. Agaba EI, Duguru M, Agaba PA, Angbazo D. Serum lipid profile of Nigerian Diabetics with End Stage Renal Diease. West Afr J Med. 2005 Oct-Dec, 24(4):305-8.
31. Hirano T, Sakaue T, Misaki A. Very low-density lipoproteinapoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII.
Kidney Int 2003; 63: 2171-77.
32. Vasilis T, Zoi M, Moses E. Dyslipidemia associated with Chronic Kidney Disease. The Open Cardiovascular Medicine journal 2011; 5:41 -48.
33. Liang K, Vaziri ND. Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
Nephrol Dial Transplant .1997; 12: 1381-6.
34. Victor B. Dyslipidemia in Chronic Renal Failure. International Federation of Clinical Chemistry and Laboratory Medicine Annual Report 2009 1,2.
35. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am. J. Physiol. Renal Physiol 2006; 290:
F262–F272.
36. Sato T, Liang K, Vaziri ND. Protein restriction and AST‑120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int. 2003; 64, 1780–1786.
37. Kim C, Vaziri ND. Downregulation of hepatic LDL receptor‑related protein (LRP) in chronic renal failure. Kidney Int. 2005; 67, 1028–1032.
38. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of HDL in chronic kidney disease. Transl. Res. 2009; 153, 77–85.
72
39. Vaziri ND, Liang, K. Parks, J.S. Downregulation of hepatic lecithin:cholesterol acyltransferase (LCAT) gene expression in chronic renal failure. Kidney Int. 2001; 59, 2192–2196.
40. Liang K, Vaziri ND. Upregulation of acyl‑CoA: cholesterol acyltransferase (ACAT) in chronic renal failure. Am. J. Physiol. Endocrinol. Metab. 2002;
283, e676–e681.
41. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am. J. Physiol. Renal Physiol. 2004; 287, F1038–F1043.
42. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M.
HDL Inflammatory Index correlate with poor outcomes in HDL patients;
Kidney Int.2007; 72: 1149-56.
43. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti‑inflammatory activity and inhibition of LDL pro‑inflammatory activity in the plasma of patients with end‑stage renal disease by an apoA‑1 mimetic peptide. Kidney Int. 2009;76, 437–444.
44. Harper RC, Jacobson TA. Managing Dyslipidemia in CKD. J Am Coll Cardiol 2008; 51: 2375-2384.
45. Ansell BJ. Inflammatory/anti-inflammatory properties of high‑density lipoprotein distinguish patients from control subjects better than highdenisty lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108, 2751–2756.
46. Van henten BJ, Reddy ST, Navab M, Fogel AM. Understanding changes in high density lipoproteins during the acute phase response. Artherioscle Thromb Vasc Biol 2006; 26: 1687-88.
73
47. Fliser D, Pacini G, Engelleiter R. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-7.
48. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002; 51:
1226-32.
49. Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, Peake PW. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism 2005; 54: 821-8.
50. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003; 84: S121-4.
51. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996; 50: 1928-35.
52. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996; 49: 1360-71.
53. Chan DT, Dogra GK, Irish AB. Chronic kidney disease delays VLDL apoB-100 particle catabolism: potential role of apo C-III. J Lipid Res 2009; 50:
2524-31.
54. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 1999; 25: 258-62.
55. Bagdade J, Casaretto A, Albers J. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 1976; 87: 38-48.
74
56. Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990; 37: 854-8.
57. Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol 1997; 273: F925-30.
58. Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995; 47: 579-86.
59. Warwick GL, Packard CJ. Lipoprotein metabolism in the nephritic syndrome. Nephrol Dial Transplant 1993; 8: 385-96.
60. Liang K, Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 1997; 130: 387-94.
61. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome.Kidney Int. 2001; 59:179 -89
62. Moorhead JF, Chan MK, El-Nahas M, Varghese Z.Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet.
1982 Dec 11;2(8311):1309-11.
63. Gyebi L, Soltani Z, Reisin E.Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep. 2012 Apr;14(2):177-81.
64. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, and Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084–2091, 2003
75
65. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908–1919.
66. Moorhead JF, Chan MK, El-Nahas M, Varghese Z Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet.
1982 11;2(8311):1309-11.
67. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP.
Hyperlipidemia and progressive renal disease. Kidney Int Suppl. 1991, 31:S41-8.
68. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P.
Dialysis modalities and dyslipidemia. Kidney Int Suppl 2003; 63: S110-S112.
69. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297–304.
70. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004;44:61–7.
71. Hassan T. Inferential statistics. In: Bankole MA (Ed) Handbook of Research Methods in Medicine. National Postgraduate Medical College of Nigeria. 1991; 171-211.
72. Greenwald I. The chemistry of Jaffe's reaction for creatinine II. The effect of substitution in the creatinine molecule and a possible formula for the red tautomer. J. Am. Chem. Soc., 1925, 47 (5):1443–1448.
73. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol.2007;
18:1246–61.
76
74. Montague T, Murphy B. Lipid management in chronic kidney disease, hemodialysis, and transplantation. Endocrinol Metab Clin North Am.2009;
38:223–34.
75. Wanner C, Quaschning T. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens.2001;10:195–
201.
76. Attman PO, Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol. 2009; 20:293–9.
77. Roberto Scarpioni, Marco Ricardi, Vittorio Albertazzi, Luigi MelfaTreatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World J Nephrol 2012 December 6; 1(6): 184-194 78. Khalid M, Masood J, Muhammad A, Muhammad N, Abdul Q: Pattern of
Dyslipidemia in patients with CRF. Prof. Med J 2006;13 (1): 79-84.
79. Biara D, Joshi V, Shah T, Gandha K, Modi N. Impact of hemodialysis on lipid profile among chronic renal failure patients. Int. J Sci, Research pub, 2013 (3) 7;2250-3135.
80. Docci D, Capponcini C, Mengozzi S, Baldrati L, Neri L, Feletti C: Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients. Nephron 1995 ; 69: 323–326.
81. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J: Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19 : 2570– 2575.
82. Jung K, Scheifler A, Schulze BD, Scholz M: Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate. Am J Kidney Dis 1995;
25: 584–588.
77
83. Ojogwu LI, Anah CO. Renal failure and hypertension in tropical Africa—a pre-dialysis experience from Nigeria. East African Medical Journal, 1983;
60(7):478–484.
84. Keane WF. Nephrology forum: Lipids and the kidney. Kid. Intern. 1994;
46: 910 – 20.
78
APPENDICES